NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
NeOnc Technologies (NASDAQ: NTHI) announced that its wholly owned subsidiary NuroMENA signed a Master Services Agreement (MSA) with UAE-based contract research organization IROS, part of the M42 group, to support clinical development in the Middle East on October 9, 2025. The MSA grants NuroMENA access to Abu Dhabi’s health ecosystem, AI/technology and genomics capabilities to accelerate NeOnc’s Phase 2 CNS cancer programs.
Concurrently, NuroMENA expanded its board to add two Quazar Investment representatives, including CEO Waleed K. Al Ali and the Quazar chairman, joining existing directors Amir Heshmatpour, Dr. Ishwar K. Puri and Bader Al Monawer to oversee regional strategy.
NeOnc Technologies (NASDAQ: NTHI) ha annunciato che la sua filiale interamente controllata NuroMENA ha firmato un Master Services Agreement (MSA) con l'organizzazione di ricerca clinica basata negli EAU IROS, parte del gruppo M42, per supportare lo sviluppo clinico nel Medio Oriente il 9 ottobre 2025. L'MSA garantisce a NuroMENA l'accesso all'ecosistema sanitario di Abu Dhabi, alle capacità di AI/tecnologia e genomica per accelerare i programmi di CNS di fase 2 di NeOnc.
Contemporaneamente, NuroMENA ha ampliato il suo consiglio di amministrazione per includere due rappresentanti di Quazar Investment, tra cui il CEO Waleed K. Al Ali e il presidente di Quazar, affiancando gli attuali membri Amir Heshmatpour, il Dott. Ishwar K. Puri e Bader Al Monawer per supervisionare la strategia regionale.
NeOnc Technologies (NASDAQ: NTHI) anunció que su filial 100% propiedad NuroMENA firmó un Master Services Agreement (MSA) con la organización de investigación clínica con base en los EAU IROS, parte del grupo M42, para apoyar el desarrollo clínico en Oriente Medio el 9 de octubre de 2025. El MSA otorga a NuroMENA acceso al ecosistema de salud de Abu Dhabi, capacidades de IA/tecnología y genómica para acelerar los programas de CNS de fase 2 de NeOnc.
Paralelamente, NuroMENA amplió su junta para incorporar a dos representantes de Quazar Investment, incluido el CEO Waleed K. Al Ali y el presidente de Quazar, uniéndose a los directores existentes Amir Heshmatpour, el Dr. Ishwar K. Puri y Bader Al Monawer para supervisar la estrategia regional.
NeOnc Technologies (NASDAQ: NTHI)는 완전 자회사 NuroMENA가 중동 지역 임상 개발을 지원하기 위해 UAE 기반 계약 연구 기관 IROS, M42 그룹의 일부와 2025년 10월 9일에 MASTER SERVICES AGREEMENT(MSA)를 체결했다고 발표했습니다. MSA는 NuroMENA에게 아부다비의 헬스 생태계, AI/기술 및 게놈학 역량에 대한 접근을 제공하여 NeOnc의 2상 CNS 암 프로그램을 가속화합니다.
동시에 NuroMENA는 Quazar Investment의 두 명의 대표를 이사회에 추가하도록 확장했으며, CEO Waleed K. Al Ali와 Quazar 의장이 포함되어 Amir Heshmatpour, Dr. Ishwar K. Puri, Bader Al Monawer와 함께 지역 전략을 감독합니다.
NeOnc Technologies (NASDAQ: NTHI) a annoncé que sa filiale 100 % détenue NuroMENA a signé un Master Services Agreement (MSA) avec l'organisation de recherche clinique basée aux Émirats arabes unis IROS, faisant partie du groupe M42, pour soutenir le développement clinique au Moyen-Orient le 9 octobre 2025. Le MSA donne à NuroMENA accès à l'écosystème sanitaire d'Abou Dhabi, aux capacités d'IA/technologie et de génomique pour accélérer les programmes de cancer CNS de phase 2 de NeOnc.
Parallèlement, NuroMENA a élargi son conseil d'administration pour y faire entrer deux représentants de Quazar Investment, dont le PDG Waleed K. Al Ali et le président de Quazar, rejoignant les administrateurs actuels Amir Heshmatpour, le Dr. Ishwar K. Puri et Bader Al Monawer pour superviser la stratégie régionale.
NeOnc Technologies (NASDAQ: NTHI) gab bekannt, dass seine vollständig im Besitz befindliche Tochtergesellschaft NuroMENA eine Master Services Agreement (MSA) mit der in den VAE ansässigen Vertragsforschungsorganisation IROS, Teil der M42-Gruppe, unterzeichnet hat, um die klinische Entwicklung im Nahen Osten am 9. Oktober 2025 zu unterstützen. Die MSA gewährt NuroMENA Zugriff auf Abu Dhabis Gesundheitsökosystem, KI-/Technologie- und Genomikfähigkeiten, um NeOncs Phase-2-CNS-Krebsprogramme zu beschleunigen.
Gleichzeitig hat NuroMENA seinen Vorstand erweitert, um zwei Vertreter von Quazar Investment aufzunehmen, darunter der CEO Waleed K. Al Ali und der Vorsitzende von Quazar, die bestehenden Direktoren Amir Heshmatpour, Dr. Ishwar K. Puri und Bader Al Monawer zu unterstützen, um die regionale Strategie zu überwachen.
NeOnc Technologies (NASDAQ: NTHI) أعلنت أن شركتها التابعة المملوكة بالكامل NuroMENA وقّعت على اتفاقية خدمات رئيسية (MSA) مع منظمة أبحاث سريرية مقرها الإمارات العربية المتحدة IROS، جزء من مجموعة M42، لدعم التطوير السريري في الشرق الأوسط في 9 أكتوبر 2025. تمنح الـ MSA لـ NuroMENA الوصول إلى منظومة الصحة في أبوظبي، وقدرات الذكاء الاصطناعي/التقنية والجينوميات لتسريع برامج NeOnc لسرطان الجهاز العصبي المركزي (CNS) في المرحلة الثانية.
في الوقت نفسه، قامت NuroMENA بتوسيع مجلس إدارتها لإضافة اثنين من ممثلي Quazar Investment، بمن فيهم المدير التنفيذي Waleed K. Al Ali ورئيس مجلس إدارة Quazar، لينضموا إلى الأعضاء الحاليين أمير هشتمةبور، الدكتور إيشوار ك. بوْري وبدر المعونر للإشراف على الاستراتيجية الإقليمية.
NeOnc Technologies (NASDAQ: NTHI) 宣布其全资子公司 NuroMENA 已与位于阿联酋的合同研究机构 IROS（属于 M42 集团）签署主服务协议（MSA），以在 2025年10月9日 支持中东地区的临床开发。该MSA 赋予 NuroMENA 进入阿布扎比的健康生态系统、人工智能/技术及基因组学能力，以加速 NeOnc 的二期中枢神经系统癌症(CNS)项目。
同时，NuroMENA 扩大了董事会，增聘两名来自 Quazar Investment 的代表，其中包括首席执行官 Waleed K. Al Ali 和 Quazar 的董事长，加入现有董事 Amir Heshmatpour、Ishwar K. Puri 博士与 Bader Al Monawer，共同监督区域战略。
- None.
- None.
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group — a global health company powered by Artificial Intelligence (AI), technology and genomics.
In a concurrent strategic move, NeOnc is expanding the NuroMENA Board of Directors, appointing key partners from Quazar Investment to drive regional governance and growth.
The MSA with IROS provides NuroMENA with access to a world-class health ecosystem to accelerate the clinical development of NeOnc’s innovative cancer therapies. This partnership with an M42 entity represents a powerful validation of NeOnc’s scientific platform and anchors its clinical trial operations within one of the world's most advanced healthcare infrastructures.
To guide this new phase of growth, the NuroMENA board will be expanded to include two new members: Waleed K. Al Ali, the CEO of Quazar Investment, and the Chairman of Quazar Investment. They will serve alongside current NuroMENA directors Amir Heshmatpour, Dr. Ishwar K. Puri and Bader Al Monawer, creating a formidable leadership team to oversee the company's regional strategy.
“Signing an agreement with IROS, an entity backed by a global force like M42, is a transformative event,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “This MSA provides the elite infrastructure needed to fast-track our clinical trials. By simultaneously installing a powerful board with our partners at Quazar, we are establishing a premier foundation for both operational excellence and strategic leadership in the Middle East. Together, these actions will dramatically accelerate our mission to bring novel cancer treatments to patients.”
Commenting on the agreement, Islam Eltantawy, General Manager at IROS, said: “At IROS, we are proud to provide the platform, infrastructure and expertise that enable companies like NeOnc to accelerate the development of breakthrough cancer therapies. Through Abu Dhabi’s world-class health ecosystem that is fully aligned with international standards, we are able to conduct clinical trials with exceptional speed, quality and integrity. This partnership reflects our shared commitment to advancing research that brings new hope to patients and positions Abu Dhabi as a global hub for clinical excellence and innovation in oncology.”
About IROS
IROS, part of the M42 group, a global tech-enabled health powerhouse, is a pioneering UAE-based Clinical Research Organization (CRO) dedicated to advancing excellence in clinical research and real-world evidence. Its mission is to leverage cutting-edge technologies to innovate in health and drive breakthroughs in clinical research. By conducting high-quality research and achieving groundbreaking insights, IROS aims to improve patients’ lives and shape the health landscape.
IROS' comprehensive offerings spans all therapeutic domains, positioning it as a leader in regional medical research. With a team of high-caliber experts committed to precision, IROS offers both full-service solutions and tailored services to meet the unique needs of its partners. The organization continually integrates the latest technologies and techniques to drive innovation and excellence.
For more information, please visit, https://iros.ai/
About M42
M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.
Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
About NuroMENA Holdings Ltd.
NuroMENA is a UAE-based subsidiary of NeOnc Technologies Holdings, Inc., established as part of the UAE structure to oversee regional clinical operations, partnerships, and innovation in the Middle East and North Africa. Upon closing of the
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
What did NeOnc (NTHI) announce on October 9, 2025 regarding NuroMENA?
How will the IROS MSA affect NeOnc's clinical program for CNS cancers (NTHI)?
Who were the new board appointees to NuroMENA named by NeOnc (NTHI)?
Which existing NuroMENA directors will remain after NeOnc's board expansion?
Does the NeOnc (NTHI) announcement indicate commercial terms or financing amounts?
Where will NeOnc (NTHI) run the accelerated clinical trials under the IROS agreement?
